This pathway-level visualisation emphasises the polypharmacological potential of medicarpin in addressing CCA development and identifies key axes, especially the PI3K-Akt/mTOR signalling cascade, as viable treatment avenues for future validation. The gene discussed is AKT1; the disease is cholangiocarcinoma.